Startup profile · funding coverage
Proscia funding, valuation and investors
Digital-pathology workflow and AI software for laboratories and biopharma.
Keep track of Proscia
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Growth financing
$50M · March 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$50M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Philadelphia, Pennsylvania, United States
Investors in latest funding
Other: Undisclosed investors
Overview
Proscia's Concentriq platform connects pathology slide scanners, laboratory systems, image-analysis applications, AI tools, staff and data into a vendor-agnostic digital workflow.
Why Proscia is interesting
Agilent's agreement to acquire Proscia would combine diagnostic instruments and staining reagents with an open software layer, making pathology data a foundation for AI-enabled diagnostics and drug development.
Product & use cases
Concentriq provides enterprise image management, diagnostic workflows and AI integration for clinical laboratories and biopharma research.
- Primary digital pathology diagnosis.
- Biopharma research and companion diagnostics.
- AI-enabled slide analysis and pathology data management.
Key facts
- Agilent agreed to pay $240M at closing plus up to $30M in performance payments.
- Proscia reported more than $18M of trailing-twelve-month revenue.
Funding history (newest first)
Growth financing
2025-03 $50M- Undisclosed investors
Competitive landscape
Edge: FDA-cleared, vendor-agnostic software with deployments across more than 4,000 laboratories, hospitals and clinics and 16 of the top 20 pharmaceutical companies, according to the transaction announcement.
Competes with PathAI, Paige, Sectra and integrated scanner vendors. Under Agilent, its open architecture may gain distribution but could face pressure to favor the acquirer's instruments.
-
PathAI direct
AI pathology software and diagnostics workflows.
-
Paige direct
AI-assisted cancer pathology and digital workflows.
-
Sectra incumbent
Enterprise imaging and pathology IT.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Proscia's financing or category context.
FAQs about Proscia
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.